Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.18
BSX's Cash to Debt is ranked lower than
90% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. BSX: 0.18 )
Ranked among companies with meaningful Cash to Debt only.
BSX' s 10-Year Cash to Debt Range
Min: 0.03  Med: 0.15 Max: 4.11
Current: 0.18
0.03
4.11
Equity to Asset 0.38
BSX's Equity to Asset is ranked lower than
81% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. BSX: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
BSX' s 10-Year Equity to Asset Range
Min: 0.18  Med: 0.50 Max: 0.77
Current: 0.38
0.18
0.77
F-Score: 5
Z-Score: 1.12
M-Score: -2.82
WACC vs ROIC
9.42%
8.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -2.52
BSX's Operating margin (%) is ranked lower than
57% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. BSX: -2.52 )
Ranked among companies with meaningful Operating margin (%) only.
BSX' s 10-Year Operating margin (%) Range
Min: -53.36  Med: 13.64 Max: 27.99
Current: -2.52
-53.36
27.99
Net-margin (%) -2.11
BSX's Net-margin (%) is ranked lower than
56% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. BSX: -2.11 )
Ranked among companies with meaningful Net-margin (%) only.
BSX' s 10-Year Net-margin (%) Range
Min: -56.12  Med: -1.58 Max: 18.88
Current: -2.11
-56.12
18.88
ROE (%) -2.36
BSX's ROE (%) is ranked lower than
56% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. BSX: -2.36 )
Ranked among companies with meaningful ROE (%) only.
BSX' s 10-Year ROE (%) Range
Min: -44.65  Med: -1.80 Max: 30.84
Current: -2.36
-44.65
30.84
ROA (%) -0.92
BSX's ROA (%) is ranked lower than
52% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. BSX: -0.92 )
Ranked among companies with meaningful ROA (%) only.
BSX' s 10-Year ROA (%) Range
Min: -21.16  Med: -0.71 Max: 15.31
Current: -0.92
-21.16
15.31
ROC (Joel Greenblatt) (%) -9.15
BSX's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. BSX: -9.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BSX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -153.31  Med: 11.12 Max: 138.18
Current: -9.15
-153.31
138.18
Revenue Growth (3Y)(%) 3.50
BSX's Revenue Growth (3Y)(%) is ranked higher than
52% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. BSX: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BSX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.5  Med: 3.50 Max: 28.7
Current: 3.5
-10.5
28.7
EBITDA Growth (3Y)(%) -32.60
BSX's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. BSX: -32.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BSX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -72  Med: 11.40 Max: 283.2
Current: -32.6
-72
283.2
» BSX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BSX Guru Trades in Q3 2014

Ray Dalio 61,384 sh (New)
Steven Cohen 2,523,500 sh (New)
Jim Simons 2,209,905 sh (+309.09%)
Paul Tudor Jones 89,341 sh (+230.40%)
Vanguard Health Care Fund 51,242,050 sh (+19.88%)
Diamond Hill Capital 23,137,833 sh (+7.04%)
Michael Price 2,000,000 sh (unchged)
Leon Cooperman Sold Out
Dodge & Cox 44,458,338 sh (-0.92%)
PRIMECAP Management 47,079,199 sh (-2.83%)
Mario Gabelli 1,704,036 sh (-4.58%)
» More
Q4 2014

BSX Guru Trades in Q4 2014

Jim Simons 5,333,305 sh (+141.34%)
Steven Cohen 4,646,700 sh (+84.14%)
Paul Tudor Jones 162,501 sh (+81.89%)
Ray Dalio 89,184 sh (+45.29%)
Vanguard Health Care Fund 59,624,800 sh (+16.36%)
Diamond Hill Capital 23,348,194 sh (+0.91%)
Steven Cohen 750,000 sh (unchged)
PRIMECAP Management 46,957,349 sh (-0.26%)
Michael Price 1,980,000 sh (-1.00%)
Mario Gabelli 1,650,446 sh (-3.14%)
Dodge & Cox 1,184,730 sh (-97.34%)
» More
Q1 2015

BSX Guru Trades in Q1 2015

Pioneer Investments 2,749,545 sh (New)
Alan Fournier 2,880,000 sh (New)
Caxton Associates 225,000 sh (New)
Ray Dalio 111,084 sh (+24.56%)
Michael Price 1,980,000 sh (unchged)
Vanguard Health Care Fund 59,624,800 sh (unchged)
PRIMECAP Management 46,447,349 sh (-1.09%)
Diamond Hill Capital 20,427,155 sh (-12.51%)
Mario Gabelli 1,317,796 sh (-20.16%)
Jim Simons 3,793,655 sh (-28.87%)
Dodge & Cox 729,460 sh (-38.43%)
Steven Cohen 1,705,600 sh (-63.29%)
Paul Tudor Jones 20,554 sh (-87.35%)
» More
Q2 2015

BSX Guru Trades in Q2 2015

Paul Tudor Jones 650,000 sh (+3062.40%)
Steven Cohen 2,790,400 sh (+63.60%)
Pioneer Investments 3,486,551 sh (+26.80%)
Alan Fournier 3,545,000 sh (+23.09%)
Ray Dalio 118,384 sh (+6.57%)
Vanguard Health Care Fund 59,624,800 sh (unchged)
Michael Price 1,980,000 sh (unchged)
Caxton Associates Sold Out
PRIMECAP Management 46,097,564 sh (-0.75%)
Diamond Hill Capital 20,217,043 sh (-1.03%)
Dodge & Cox 588,260 sh (-19.36%)
Jim Simons 2,847,305 sh (-24.95%)
Mario Gabelli 963,296 sh (-26.90%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Boston Scientific Inc

Diamond Hill Capital Comments on Boston Scientific Corp - Oct 17, 2014

Shares of Boston Scientific Corp. (BSX) declined as investors focused on potential liabilities stemming from legal disputes. We continue to see improvement in revenue trends and believe they will be key factors in closing the discount to our estimate of intrinsic value over time.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jul 25, 2014

•Medical device manufacturer Boston Scientific Corp. (BSX) reported solid earnings for the first quarter but investors focused on near-term headwinds in the cardiac-rhythm management business. The company also announced a delay in potential approval for its Watchman’s heart device. Given the breadth of the company’s pipeline, potential for margin upside, and attractive valuation, we continue to like the outlook for the shares going forward.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jun 26, 2014

Medical device manufacturer Boston Scientific Corp. (BSX) benefitted from continued revenue acceleration and the launch of a new high margin stent with the potential for sizeable share gains.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jan 15, 2014

Boston Scientific Corp. (BSX), a medical device manufacturer, recently reported its first quarter of growth in more than three years, while also raising its earnings outlook. An emerging pipeline of new products offers the potential for continued improvement and the potential to return to mid-single digit revenue growth.

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Boston Scientific Inc

Diamond Hill Capital Comments on Boston Scientific Corp
Shares of Boston Scientific Corp. (BSX) declined as investors focused on potential liabilities stemming from legal disputes. We continue to see improvement in revenue trends and believe they will be key factors in closing the discount to our estimate of intrinsic value over time. Read more...

Ratios

vs
industry
vs
history
Forward P/E 17.15
BSX's Forward P/E is ranked higher than
67% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.31 vs. BSX: 17.15 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.40
BSX's P/B is ranked lower than
59% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. BSX: 3.40 )
Ranked among companies with meaningful P/B only.
BSX' s 10-Year P/B Range
Min: 0.59  Med: 1.39 Max: 8.33
Current: 3.4
0.59
8.33
P/S 3.00
BSX's P/S is ranked lower than
51% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. BSX: 3.00 )
Ranked among companies with meaningful P/S only.
BSX' s 10-Year P/S Range
Min: 1.02  Med: 2.22 Max: 6.84
Current: 3
1.02
6.84
PFCF 51.80
BSX's PFCF is ranked lower than
71% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 33.52 vs. BSX: 51.80 )
Ranked among companies with meaningful PFCF only.
BSX' s 10-Year PFCF Range
Min: 7.25  Med: 19.22 Max: 192.5
Current: 51.8
7.25
192.5
POCF 34.53
BSX's POCF is ranked lower than
71% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 22.08 vs. BSX: 34.53 )
Ranked among companies with meaningful POCF only.
BSX' s 10-Year POCF Range
Min: 5.67  Med: 15.02 Max: 64.6
Current: 34.53
5.67
64.6
Current Ratio 1.95
BSX's Current Ratio is ranked lower than
62% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. BSX: 1.95 )
Ranked among companies with meaningful Current Ratio only.
BSX' s 10-Year Current Ratio Range
Min: 0.52  Med: 1.51 Max: 3.46
Current: 1.95
0.52
3.46
Quick Ratio 1.45
BSX's Quick Ratio is ranked lower than
64% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. BSX: 1.45 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s 10-Year Quick Ratio Range
Min: 0.33  Med: 1.17 Max: 2.56
Current: 1.45
0.33
2.56
Days Inventory 161.89
BSX's Days Inventory is ranked lower than
62% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. BSX: 161.89 )
Ranked among companies with meaningful Days Inventory only.
BSX' s 10-Year Days Inventory Range
Min: 90.54  Med: 125.34 Max: 236.5
Current: 161.89
90.54
236.5
Days Sales Outstanding 59.39
BSX's Days Sales Outstanding is ranked higher than
64% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. BSX: 59.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s 10-Year Days Sales Outstanding Range
Min: 49.46  Med: 61.29 Max: 87.9
Current: 59.39
49.46
87.9

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.12
BSX's Price/Projected FCF is ranked lower than
56% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. BSX: 2.12 )
Ranked among companies with meaningful Price/Projected FCF only.
BSX' s 10-Year Price/Projected FCF Range
Min: 0.5  Med: 1.38 Max: 5.76
Current: 2.12
0.5
5.76
Price/Median PS Value 1.36
BSX's Price/Median PS Value is ranked lower than
71% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. BSX: 1.36 )
Ranked among companies with meaningful Price/Median PS Value only.
BSX' s 10-Year Price/Median PS Value Range
Min: 0.48  Med: 1.41 Max: 4.3
Current: 1.36
0.48
4.3
Price/Peter Lynch Fair Value 0.94
BSX's Price/Peter Lynch Fair Value is ranked lower than
1011% of the 38 Companies
in the Global Medical Devices industry.

( Industry Median: 2.21 vs. BSX: 0.94 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BSX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.82  Med: 1.49 Max: 8.56
Current: 0.94
0.82
8.56
Earnings Yield (Greenblatt) (%) -0.79
BSX's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. BSX: -0.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BSX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -0.82  Med: 4.10 Max: 9
Current: -0.79
-0.82
9
Forward Rate of Return (Yacktman) (%) 50.18
BSX's Forward Rate of Return (Yacktman) (%) is ranked higher than
98% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 4.79 vs. BSX: 50.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BSX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 3.1  Med: 7.30 Max: 49.3
Current: 50.18
3.1
49.3

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 7,374 7,666 8,030
EPS($) 0.79 0.96 0.99
EPS without NRI($) 0.79 0.96 0.99

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:BSX.Germany,
Boston Scientific Inc is a developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. The Company's products were offered for sale by seven core businesses - Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, Peripheral Interventions (PI), Urology and Women's Health, Neuromodulation, and Electrophysiology (EP). market a broad portfolio of internally-developed and self-manufactured drug-eluting stents including the Promus Element and Promus Element Plus everolimus-eluting stents, as well as its TAXUS Element and Ion paclitaxel-eluting stents. The Company sell various products designed to treat patients with peripheral disease (disease which appears in blood vessels other than in the heart and in the biliary tree), including a broad line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. Its peripheral angioplasty balloon technology includes its next-generation Mustang PTA balloon, its Coyote balloon catheter, a deliverable and ultra-low profile balloon dilatation catheter designed for a wide range of peripheral angioplasty procedures, and its Charger PTA Balloon Catheter, a 0.035" percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company also sell products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continue to market its extensive line of Interventional Oncology product solutions, including the recently launched Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company develop, manufacture and market a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardioverter defibrillator (ICD), Implantable pacemaker systems. During 2013, the company marketed its products to over 13,000 hospitals, clinics, outpatient facilities and medical offices in approximately 100 countries. The Company is subject to various environmental laws, directives and regulations both in the U.S. and abroad. Its operations, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes.
» More Articles for BSX

Headlines

Articles On GuruFocus.com
Endo Pharmaceuticals Posts A Solid Q1 Earnings Report May 12 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
Diamond Hill Select Fund Q4 2014 Commentary Mar 17 2015 
Boston Scientific Finally Wins Positive Nod For Watchman Heart Device In U.S. Leaving Investors Impr Mar 17 2015 
Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 
Enphase Energy (ENPH) Record-Breaking Growth, Boston Scientific (BSX) and Johnson & Johnson (JNJ) En Feb 18 2015 
A Robust Q4 Earnings Report From Boston Scientific Feb 10 2015 
Edwards Lifesciences a Gold Standard in the Market Dec 16 2014 
Boston Scientific Lost the First Place in Innovation Dec 11 2014 
Diamond Hill Capital Comments on Boston Scientific Corp Oct 17 2014 

More From Other Websites
Boston Scientific To Participate In 2015 Morgan Stanley Global Healthcare Conference Sep 02 2015
Boston Scientific To Participate In 2015 Morgan Stanley Global Healthcare Conference Sep 02 2015
Edited Transcript of BSX earnings conference call or presentation 22-Oct-14 12:00pm GMT Aug 31 2015
Boston Scientific (BSX) Stock Upgraded at Goldman Sachs Aug 27 2015
Goldman Remains Constructive on MedTech, Sees 'New Opportunities' Amid Selloff Aug 27 2015
Boston Scientific upgraded by Goldman Aug 27 2015
Boston Scientific Expands Globally, Fights Currency Woes Aug 26 2015
Boston Scientific To Participate In The 2015 Wells Fargo Healthcare Conference Aug 26 2015
Boston Scientific To Participate In The 2015 Wells Fargo Healthcare Conference Aug 26 2015
Boston Scientific's ICD, CRT-D Win CE Mark for MRI Safety Aug 25 2015
Boston Scientific Announces CE Mark For MRI Compatible Labeling For ICD And CRT-D Systems Aug 24 2015
Boston Scientific's Innova Stent System Wins FDA Approval Aug 20 2015
Boston Scientific Announces FDA Approval of Innova™ Vascular Self-Expanding Stent System Aug 20 2015
Boston Scientific Announces FDA Approval of Innova™ Vascular Self-Expanding Stent System Aug 19 2015
Houston health tech CEO steps down, starts new venture Aug 14 2015
BOSTON SCIENTIFIC CORP Financials Aug 13 2015
Sonova Holding AG : Relatively good pick today? Aug 13 2015
Analysts' Actions -- Capital One, Merck, Microsoft and More Aug 13 2015
Boston Scientific Announces Equity Investment And Sales Cooperation Agreement With Preventice... Aug 10 2015
Boston Scientific Corp. Earnings Q2*, 2015 Aug 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK